Browse SLC45A2

Summary
SymbolSLC45A2
Namesolute carrier family 45, member 2
Aliases OCA4; MATP; membrane associated transporter; 1A1; SHEP5; melanoma antigen AIM1; protein AIM-1; underwhite; S ......
Chromosomal Location5p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Melanosome membrane Multi-pass membrane protein
Domain -
Function

Melanocyte differentiation antigen. May transport substances required for melanin biosynthesis (By similarity).

> Gene Ontology
 
Biological Process GO:0006582 melanin metabolic process
GO:0007601 visual perception
GO:0008643 carbohydrate transport
GO:0015766 disaccharide transport
GO:0015770 sucrose transport
GO:0015772 oligosaccharide transport
GO:0018958 phenol-containing compound metabolic process
GO:0019748 secondary metabolic process
GO:0042438 melanin biosynthetic process
GO:0042440 pigment metabolic process
GO:0043473 pigmentation
GO:0044550 secondary metabolite biosynthetic process
GO:0046148 pigment biosynthetic process
GO:0046189 phenol-containing compound biosynthetic process
GO:0048066 developmental pigmentation
GO:0050953 sensory perception of light stimulus
GO:1901615 organic hydroxy compound metabolic process
GO:1901617 organic hydroxy compound biosynthetic process
Molecular Function GO:0005351 sugar:proton symporter activity
GO:0005402 cation:sugar symporter activity
GO:0008506 sucrose:proton symporter activity
GO:0008515 sucrose transmembrane transporter activity
GO:0015144 carbohydrate transmembrane transporter activity
GO:0015154 disaccharide transmembrane transporter activity
GO:0015157 oligosaccharide transmembrane transporter activity
GO:0015291 secondary active transmembrane transporter activity
GO:0015293 symporter activity
GO:0015294 solute:cation symporter activity
GO:0015295 solute:proton symporter activity
GO:0022804 active transmembrane transporter activity
GO:0051119 sugar transmembrane transporter activity
GO:1901476 carbohydrate transporter activity
Cellular Component GO:0030659 cytoplasmic vesicle membrane
GO:0033162 melanosome membrane
GO:0042470 melanosome
GO:0045009 chitosome
GO:0048770 pigment granule
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-5662702: Melanin biosynthesis
R-HSA-1430728: Metabolism
R-HSA-71291: Metabolism of amino acids and derivatives
Summary
SymbolSLC45A2
Namesolute carrier family 45, member 2
Aliases OCA4; MATP; membrane associated transporter; 1A1; SHEP5; melanoma antigen AIM1; protein AIM-1; underwhite; S ......
Chromosomal Location5p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SLC45A2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between SLC45A2 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
28630054MelanomaImmunotherapy targetAntigen-specific CTLs generated against HLA-A*0201- and HLA-A*2402-restricted SLC45A2 peptides effectively killed a majority of HLA-matched cutaneous, uveal, and mucosal melanoma cell lines tested (18/25).
Summary
SymbolSLC45A2
Namesolute carrier family 45, member 2
Aliases OCA4; MATP; membrane associated transporter; 1A1; SHEP5; melanoma antigen AIM1; protein AIM-1; underwhite; S ......
Chromosomal Location5p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SLC45A2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolSLC45A2
Namesolute carrier family 45, member 2
Aliases OCA4; MATP; membrane associated transporter; 1A1; SHEP5; melanoma antigen AIM1; protein AIM-1; underwhite; S ......
Chromosomal Location5p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SLC45A2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.9090.402
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)653.2160.224
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.7880.726
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.3880.597
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.0350.978
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.9220.536
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.3450.719
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-1.1960.519
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11122.0170.324
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.5560.279
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.7620.267
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.2310.293
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SLC45A2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSLC45A2
Namesolute carrier family 45, member 2
Aliases OCA4; MATP; membrane associated transporter; 1A1; SHEP5; melanoma antigen AIM1; protein AIM-1; underwhite; S ......
Chromosomal Location5p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SLC45A2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSLC45A2
Namesolute carrier family 45, member 2
Aliases OCA4; MATP; membrane associated transporter; 1A1; SHEP5; melanoma antigen AIM1; protein AIM-1; underwhite; S ......
Chromosomal Location5p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SLC45A2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SLC45A2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSLC45A2
Namesolute carrier family 45, member 2
Aliases OCA4; MATP; membrane associated transporter; 1A1; SHEP5; melanoma antigen AIM1; protein AIM-1; underwhite; S ......
Chromosomal Location5p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SLC45A2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSLC45A2
Namesolute carrier family 45, member 2
Aliases OCA4; MATP; membrane associated transporter; 1A1; SHEP5; melanoma antigen AIM1; protein AIM-1; underwhite; S ......
Chromosomal Location5p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SLC45A2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSLC45A2
Namesolute carrier family 45, member 2
Aliases OCA4; MATP; membrane associated transporter; 1A1; SHEP5; melanoma antigen AIM1; protein AIM-1; underwhite; S ......
Chromosomal Location5p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SLC45A2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSLC45A2
Namesolute carrier family 45, member 2
Aliases OCA4; MATP; membrane associated transporter; 1A1; SHEP5; melanoma antigen AIM1; protein AIM-1; underwhite; S ......
Chromosomal Location5p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SLC45A2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.